These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16184044)

  • 1. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
    Petersen K; Riddle MS; Jones LE; Furtek KJ; Christensen AR; Tasker SA; Hale BR
    AIDS; 2005 Oct; 19(15):1700-2. PubMed ID: 16184044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
    Rekić D; Clewe O; Röshammar D; Flamholc L; Sönnerborg A; Ormaasen V; Gisslén M; Abelö A; Ashton M
    AAPS J; 2011 Dec; 13(4):598-605. PubMed ID: 21913053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.
    Morello J; Alvarez E; Cuenca L; Vispo E; González-Lahoz J; Soriano V; Rodríguez-Nóvoa S
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1043-5. PubMed ID: 21348813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
    Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
    HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
    Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
    HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
    Rekić D; Röshammar D; Bergstrand M; Tarning J; Calcagno A; D'Avolio A; Ormaasen V; Vigan M; Barrail-Tran A; Ashton M; Gisslén M; Äbelö A
    AAPS J; 2013 Apr; 15(2):308-15. PubMed ID: 23224752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI monotherapy effective as maintenance.
    AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atazanavir: clinical use.
    Bartlett JG
    Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
    [No Abstract]   [Full Text] [Related]  

  • 10. Report from the 13th retrovirus conference. Extending the role of atazanavir.
    Feinberg J
    AIDS Clin Care; 2006 Apr; 18(4):38. PubMed ID: 16718882
    [No Abstract]   [Full Text] [Related]  

  • 11. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
    Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
    AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
    Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
    HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
    TreatmentUpdate; 2008 Mar; 20(2):7-8. PubMed ID: 18661646
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
    Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
    J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
    Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
    J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
    Sax PE
    AIDS Clin Care; 2008 Dec; 20(12):98. PubMed ID: 19271333
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.